International Advisory Board

The HRB-TMRN benefits from the advisory services of a highly experienced external International Advisory Board. The board comprises of both national and international members, each bringing substantial knowledge relevant to the network.

  • Dr Derick Mitchell
    Dr Derick Mitchell

    Derick Mitchell, PhD. is the Chief Executive of the Irish Platform for Patient Organisations, Science and Industry (IPPOSI – IPPOSI is a unique, patient-led partnership between patient groups, scientists, industry and other key decision makers, which builds consensus on issues relevant to all involved in delivering health innovations to people with unmet medical needs. Derick has over ten years experience of working in patient involvement, scientific communications, multi-stakeholder management and advocacy at both the national and European level. Derick leads IPPOSI’s participation in the European Patients Academy (EUPATI), an initiative which is training patients to become involved in the medicines R&D process, and has spread the IPPOSI public-private partnership model to over 20 countries. Derick is a member of a number of national and international boards including the EHealth Ireland committee; the oversight committee for the National Rare Disease Plan; the Medical and Life Sciences Committee of the Royal Irish Academy, the HIQA Research Ethics & HTA Advisory Boards, among others. Derick graduated with a BSc. (Hons) in Biotechnology from NUI Galway (2000) followed by a PhD in Molecular Medicine from University College Dublin (2004). Outside of IPPOSI, Derick spends his free time attempting to influence his two toddler daughters.

  • Prof. Paula Williamson
    Prof. Paula Williamson

    Paula Williamson is Professor of Biostatistics. She is Director of the MRC North West Hub for Trials Methodology Research (HTMR), Director of the Clinical Trials Research Centre (CTRC), and Head of the Department of Biostatistics at the University of Liverpool. Paula chairs the University of Liverpool’s Health and Biomedical Informatics Group and is a member of the Farr Institute through HeRC North. Paula co-founded and has led the COMET (Core Outcome Measures in Effectiveness Trials) Initiative since 2010. She was appointed as an NIHR Senior Investigator in 2014, gave the Bradford Hill Lecture in 2017, and is current Chair of the MRC HTMR Network.

  • Prof. Tom Fahey
    Prof. Tom Fahey

    Tom Fahey is Professor of General Practice, RCSI Medical School and Principal Investigator for the HRB Centre for Primary Care Research ( He has extensive experience in the design, conduct, analysis and reporting of RCTs having published over 15 RCTs in primary care settings. He also has an interest in the metrics of external validity of RCTs and their relevance to clinical practice. He is responsible for the running of the RCT and systematic review module of the HRB SPHeRE programme and runs a short course in research methods twice a year in RCSI.

  • Prof. Alan Montgomery
    Prof. Alan Montgomery

    Prof Montgomery is Professor of Medical Statistics and Clinical Trials at the Nottingham Clinical Trials Unit, University of Nottingham. Alan’s research is in the design, conduct, analysis and reporting of pragmatic phase III randomised trials, and in methodological research to increase the evidence base for the efficient conduct of such trials. He is currently a member of the NIHR Health Technology Assessment programme Clinical Evaluation and Trials funding board.

  • Dr David Moher
    Dr David Moher

    Dr. David Moher is a senior scientist, clinical epidemiology program, Ottawa Hospital Research Institute, where he directs the centre for journalology (publication science) ( ). Dr. Moher is also an Associate Professor, School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, where he holds a University Research Chair. Dr. Moher holds an MSc in epidemiology and PhD in clinical epidemiology and biostatistics.Dr. Moher has been involved in developing the science of how to optimally conduct and report systematic reviews for most of his professional career. Another part of his research has focused on how best to develop reporting guidelines. He spearheaded the development of the CONSORT statement and the PRISMA statement. He has been actively involved in the development of many other reporting guidelines and is part of the EQUATOR Network. Dr. Moher leads an active program investigating predatory journals and publishers. More recently Dr. Moher led a program to develop core competencies for scientific journal editors. He is actively developing a program to investigate alternatives to current incentives and rewards in academic medicine. Dr. Moher has been recognized several times as a Clarivate Analytics Highly Cited Researcher (Web of Science).

  • Dr Erika Daly
    Dr Erika Daly

    Dr Erika Daly is Director Biostatistics at ICON plc, a top-5 global CRO (contract research organisation) in the pharmaceutical industry, based at ICON’s global headquarters in Dublin, Ireland. She joined ICON Clinical Research as a statistician in 2004 and has supported clinical trials in many therapeutic areas including oncology, CNS, GI disorders, and cardiovascular diseases. Initially a project statistician, she has been in management roles of increasing responsibility since 2008. As a statistical consultant, she has represented pharma companies in their discussions with the FDA and has served as the unblinded statistician for numerous data monitoring committees (DMCs). Dr Daly obtained her B.A. (Statistics and Economics), M.Sc. (Statistics) and Ph.D. (Biostatistics) from University College Dublin. She is a Chartered Statistician with the Royal Statistical Society, a former member of the PSI (Statisticians in the Pharmaceutical Industry) Scientific Committee and currently sits on the PSI Regulatory Affairs Committee. Research interests include analysis methods for matched binary and time-to-event data, multivariate modelling and trial design.

  • Prof. Shaun Treweek
    Prof. Shaun Treweek

    Shaun is a health services researcher interested in efficient trial design, particularly around recruitment and retention and the effective presentation of research evidence. He leads an initiative called Trial Forge ( that aims to be more systematic about how we generate and use research evidence in making trial design, conduct, analysis and reporting decisions.

  • Dr. Fionnuala Keane
    Dr. Fionnuala Keane

    Dr Fionnuala Keane graduated in 1994 with a B.Sc. Honours in Biochemistry and in 1999 with a PhD in Biochemistry from the National University of Ireland Galway. From Oct 1999 to Feb 2001 Fionnuala worked as a Postdoctoral Research Fellow in molecular biology and neurochemistry at the Department of Biochemistry, UCD. She joined Novartis Ireland Ltd in Feb 2001 and worked there as a Central Nervous System Hospital Specialist with the sales and marketing team until June 2003. At this point Fionnuala joined ICORG, the All Ireland Co-operative Oncology Research Group and she remained in ICORG from July 2003 to May 2014. Fionnuala was appointed to the role of Development Lead for the HRB CRCI in May 2014 to develop and deliver a 5 year business plan in line with the HRB strategic objectives, working in close collaboration with the CRF/C directors. In May 2015 Fionnuala was appointed to the role of Chief Operating Officer for the HRB CRCI.

  • Prof. Helen Whelton

    Professor Helen Whelton is Head of the College of Medicine and Health, UCC and Chief Academic Officer to the SSWHG since October 2017. Prior to this she was Dean of the School of Dentistry, University of Leeds, UK. Professor Whelton is PI of a large EU H 2020 grant to explore the use of Big Data in dentistry, involving eight national and private insurers in six EU countries. Previously, in UCC she was Vice Head of the College, Dean of the Graduate School in the College of Medicine and Health, Professor of Dental Public Health and Director of the Oral Health Services Research Centre, which is a WHO Collaborating Centre. Outside of dentistry Helen has served on the board of the Irish Health Research Board, the National Obesity Task Force and the Irish Women’s Health Council. She is a recent past President of the International Association for Dental Research, which is the largest global dental research organisation and based in Washington DC.

  • Prof. Joe Eustace

    Joe Eustace, Professor of Medicine, Consultant Nephrologist and the Director of the Clinical Research Facility, Cork. Professor Eustace graduated from University College Dublin in 1990, undertook postgraduate training in General Internal Medicine and Nephrology in Dublin and from 1996-1999 he undertook a Clinical Nephrology Fellowship in Johns Hopkins University Hospital, Baltimore; and a NIH Fellowship in Clinical Epidemiology at the Bloomberg School of Public Health as part of which he completed a MHS degree. He was subsequently appointed to the Johns Hopkins Faculty of Medicine and Clinical Epidemiology as an Assistant Professor and while at Hopkins served as Director of Ambulatory Dialysis Services and as State Commissioner in the Maryland Kidney Commission. He returned to Ireland to take up the position of Consultant Nephrologist at Cork University Hospital in 2005 and was appointed Professor and Director of the HRB Clinical Research Facility at UCC in 2011. He is an Executive Committee Member of HRB Trials’ Methodology Research Network. His research has been funded by the NIH (NIDDK), National Kidney Foundation, Johns Hopkins Clinical Scientist Award and the Health Research Board. He has authored or co-authored over 90 peer reviewed original scientific papers, and written 8 book chapters. His current research focus is on Vascular and Bone Health in Renal Transplant Recipients.

  • Dr. Ray McDermott
    Dr. Ray McDermott

    Dr Ray McDermott is the Chair of the Irish Clinical Oncology Research Group (ICORG) and recognised as an expert in the treatment of castrate-resistant prostate cancer both in Ireland and abroad. He runs a clinical trials unit which specialises in Genito-Urinary (GU) Oncology and has been involved in running over 50 studies which have accrued over 500 patients to therapeutic studies since 2005. Ray participates in Phase II and III studies in castrate-resistant disease and acts as an expert Medical Advisor to many of the pharmaceutical companies active in the area. Ray was responsible for establishing ICORG as a main member of the Eastern Cooperative Oncology Group, the leading US clinical trials network. This allows access to a broad range of studies and they have recently opened their first study in prostate cancer. He also has 3 ongoing investigator-initiated clinical studies which are successfully accruing patients around Ireland. As a clinician, Ray sees over 100 new patients with prostate cancer each year at differing stages of the disease process.

Subscribe to our Newsletter

Start typing and press Enter to search